Opinion: "While the obstacles we face may be significant, Lenacapavir represents a monumental breakthrough in the fight ...

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with drug-resistant infections in 2022. While there is still no vaccine for the ...

Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

People living with HIV need to take antiretroviral treatment for life to prevent the virus from multiplying in their body. But some people, known as 'post-treatment controllers,' have been able to ...

Engineered virus-like particles can outcompete HIV in the body, potentially offering long-term viral suppression after a single dose, a monkey study suggests. When you purchase through links on our ...

Human immunodeficiency virus, also known as HIV, is a serious viral infection that attacks the body’s immune system. Without treatment, HIV can lead to many health problems, such as acquired ...

Discover how UCSF is leading the charge in Long COVID research, uncovering key findings that advance our understanding of the condition. UCSF researchers have adapted innovative tools and ...

Recent statistics have unveiled troubling increases in HIV infection rates across the United States, particularly within diverse communities. This alarming trend highlights the importance of ...

Florida's recent decision to narrow eligibility for the Ryan White AIDS Drug Assistance Program (ADAP) is expected to limit ...

Research into this new way of treating HIV is only beginning. When it was first named in 1983, HIV was thought to be a death sentence. The virus replicated rapidly in the people it infected because ...